Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Psilocybin-Assisted Psychotherapy for Anhedonia in Treatment Resistant Depression
EF 2023-24
Résumé
Major Depressive Disorder (MDD) is rising as a significant disease burden in Canada, affecting almost 5% of the population. Anhedonia, a key feature of MDD, is characterized by the reduced ability to find pleasure or motivation in positive experiences and is observed in a variety of mood and psychological disorders. While early hypotheses linked anhedonia to dopamine deficiency, recent research suggests that there is a complex association between anhedonia and impaired neuroplasticity in brain reward circuits. Psilocybin, a psychedelic compound found in certain mushrooms, has been shown to affect neuroplasticity. This has sparked research in psilocybin-assisted psychotherapy (PAP) as a potential treatment for depression, as psilocybin is hypothesized to have the ability to rewire the brain's circuits. We are conducting a clinical trial to evaluate the optimum dose of psilocybin for antidepressant efficacy. We aim to recruit 92 participants with moderate to severe treatment resistant depression (TRD), examining one versus two doses of psilocybin over a 14-month period. We will evaluate the efficacy of psilocybin on depressive symptoms including anhedonia, which is often overlooked in research. A variety of clinical, behavioural, and cognitive assessments will be employed at specific study timepoints to assess psilocybin's effect on depression and anhedonia. We hypothesize that psilocybin may alleviate anhedonia symptoms through adaptive rewiring of the brain’s reward circuits. This study's findings hold significance in advancing treatment for anhedonia, addressing a prevalent yet undertreated core symptom of MDD, and offering hope for more effective interventions in the future.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506137
Name
Kaczmarek Erica S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Psilocybin-Assisted Psychotherapy for Anhedonia in Treatment Resistant Depression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anhedonia; Antidepressant Effects; Major Depressive Disorder; Mood Disorders; Neuroplasticity; Psilocybin; Psilocybin-Assisted Psychotherapy; Psychedelics; Treatment; Treatment Resistant Depression
Abstract
Major Depressive Disorder (MDD) is rising as a significant disease burden in Canada, affecting almost 5% of the population. Anhedonia, a key feature of MDD, is characterized by the reduced ability to find pleasure or motivation in positive experiences and is observed in a variety of mood and psychological disorders. While early hypotheses linked anhedonia to dopamine deficiency, recent research suggests that there is a complex association between anhedonia and impaired neuroplasticity in brain reward circuits. Psilocybin, a psychedelic compound found in certain mushrooms, has been shown to affect neuroplasticity. This has sparked research in psilocybin-assisted psychotherapy (PAP) as a potential treatment for depression, as psilocybin is hypothesized to have the ability to rewire the brain's circuits. We are conducting a clinical trial to evaluate the optimum dose of psilocybin for antidepressant efficacy. We aim to recruit 92 participants with moderate to severe treatment resistant depression (TRD), examining one versus two doses of psilocybin over a 14-month period. We will evaluate the efficacy of psilocybin on depressive symptoms including anhedonia, which is often overlooked in research. A variety of clinical, behavioural, and cognitive assessments will be employed at specific study timepoints to assess psilocybin's effect on depression and anhedonia. We hypothesize that psilocybin may alleviate anhedonia symptoms through adaptive rewiring of the brain’s reward circuits. This study's findings hold significance in advancing treatment for anhedonia, addressing a prevalent yet undertreated core symptom of MDD, and offering hope for more effective interventions in the future.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kaczmarek, Erica S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~